Risk Strategies Annual Education Practice Student Health Plan Survey Finds Costs Rising Nationwide
BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Risk Strategies , a leading national specialty insurance brokerage and risk management and consulting firm, today released the findings of its Annual Student Health Plan Benchmarking Survey . For the fourth consecutive year, managing student health plan costs remains the top priority for nearly 90% of educational institutions surveyed.
Conducted midyear 2024, the survey of approximately 170 colleges and universities showed an overall average plan cost rise of 7.1% with schools in the survey's Eastern region seeing increases of 10% or more. Other regions surveyed experienced more moderate hikes of 5% or less. The survey also noted a decline in enrollment in student health plans, from 29% in 2023 to 24% in 2024.
'While student health plans are generally more stable in cost than employer-based plans, they are not immune to larger pricing trends,' said Terry Lyons, National Education Practice Leader, Risk Strategies. 'Our survey shows the higher education industry is working hard to manage the issue and meet student needs.'
To address rising costs, 32% of schools indicated that they had adjusted medical benefits offerings, and 18% said they had modified the prescription drug coverage offered in the plan. The most common changes included: Higher copays and deductibles, with the average deductible increasing from $300 to $360
Shifts from copays to coinsurance for specialty drugs, rising from 12% to 27%
Increase in insurance verification for waiver/opt-out enrollment
'With plan costs increasing and enrollments in those plans declining, we see institutions working to find new ways to engage their students about the value of plan coverage,' said Elizabeth Marks, Senior Strategy Consultant, Student Health, Risk Strategies National Education Practice. 'Clarifying plan benefits and emphasizing affordability will likely be key elements of this effort.'
In other findings from this edition of the survey, mental health remained an important focus, though it ranked fourth nationally as a priority (76%) – lower than in previous years. It does remain, however, a leading priority for small schools (88%) and institutions in the East (91%). The survey also indicated that more schools (89% in 2024, up from 74% in 2023) are offering wellness programs, though smaller institutions face resource constraints.
To access the full results of the survey, please click here .
To learn more about Risk Strategies, please visit risk-strategies.com .
About Risk Strategies
Risk Strategies , part of Accession Risk Management Group , is a North American specialty brokerage firm offering comprehensive risk management services, property and casualty insurance and reinsurance placement, employee benefits, private client services, consulting services, and financial & wealth solutions. The 9th largest U.S. privately held broker, we advise businesses and personal clients, have access to all major insurance markets, and 30+ specialty industry and product line practices and experts in 200+ offices - Atlanta, Boston, Charlotte, Chicago, Dallas, Grand Cayman, Kansas City, Los Angeles, Miami, Montreal, Nashville, New York City, Philadelphia, San Francisco, Toronto, and Washington, DC. RiskStrategies.com .
Media Contact
Alana Bannan
Senior Account Executive
[email protected]
(720) 400-8025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
an hour ago
- Washington Post
Poop at work. It's good for you!
Well+Being Poop at work. It's good for you! June 6, 2025 | 2:52 PM GMT Gastroenterologist Dr. Trisha Pasricha has some tips for whether to poop on company time (yes), whether to wait (no) and how to relax while on the job.
Medscape
an hour ago
- Medscape
Experimental MS Drug Nearly Eliminates Disease Activity
PHOENIX — Frexalimab, a second-generation anti-CD40 ligand monoclonal antibody provides extended tight control of multiple sclerosis (MS) whether measured by relapse or brain imaging at 2-year follow-up, results of an open-label extension (OLE) of a phase 2 trial showed. 'At week 96, there was almost complete suppression of new gadolinium-enhancing lesions with very similar pattern seen with new or enhancing T2 lesions,' said study investigator Stephen Krieger, MD, professor of neurology, Icahn School of Medicine at Mount Sinai, New York City. Two phase 3 international studies with this drug are already enrolling. 'Part of the interest in frexalimab and anti-CD40 therapies is the idea that one can modulate both B- and T-cell activity without cell depletion,' explained Krieger, who presented the long-term open-label data on May 29 at the Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting. Near Complete Disease Suppression The latest data suggest frexalimab is fulfilling its promise. Over follow-up to date, there has been nearly complete suppression of gadolinium-enhancing (Gd+) lesions on MRI among those taking the dose now being tested in the phase 3 trials. At 2 years, with an annualized relapse rate of 0.08%, 92% of patients were relapse-free. The randomized portion of this phase 2 trial attracted attention when it was published a year ago in The New England Journal of Medicine , but the 2-year results showed that the efficacy and safety observed at 12 weeks persist. In the controlled trial, 129 patients with relapsing MS were randomized to 300-mg, 400-mg, 600-mg, or 1200-mg frexalimab or matching placebos. Suppression of Gd+ lesions was the primary endpoint. At 12 weeks, the adjusted mean of new Gd+ lesions was 1.4 in the combined placebo groups but 0.3 in the 300-mg frexalimab group and 0.2 in the 1200-mg group. Of those who participated in the randomized portion of the phase 2 trial, 97% continued into the long-term OLE. The OLE consisted of two arms: 1200-mg frexalimab administered intravenously every 4 weeks or 300-mg frexalimab administered subcutaneously every 2 weeks. At the end of 2 years, when 82% of those enrolled in the OLE were still on medication, the adjusted mean for new T1-weighted Gd+ lesions ranged from 0.1 to 0.3 across study arms whether on continuous frexalimab or switched from placebo to frexalimab. For those who were initiated on the 1200-mg dose in the controlled portion of the trial and remained on this dose for the OLE, the mean was 0.1. For the secondary endpoint of new or enlarging T2 lesions, the suppression at 2 years was almost the same. Again, the adjusted mean for new lesions across all arms ranged from 0.1 to 0.3. For those receiving the 1200-mg dose, the mean was 0.2. Mean T2 lesion volume increased in the placebo arm but not in the treatment arms during the randomized phase. After entering the OLE, T2 lesion volume fell in placebo patients now on active therapy. In the 1200-mg arm, the fall in lesion volume during the randomized phase continued into the first 24 weeks of the OLE. After 24 weeks, the lesion volume remained suppressed with no return toward baseline. Those initiated on placebo never caught up after switching to frexalimab. Relapse Rare — 2% at 96 Weeks On the 1200-mg dose of frexalimab, only 8% had any relapse recorded over the extended follow-up. In half, there was a single relapse. Only 2% had three or more relapses. While the Expanded Disability Status Scale score declined slightly among placebo patients once started on active therapy, there was no change from baseline through 96 weeks in patients started on any active therapy. As postulated by earlier preclinical and clinical studies, frexalimab had no effect on lymphocyte counts over time. Over the 96-week follow-up, levels of immunoglobulins remained unchanged, according to Krieger who showed graphs with straight lines for these values over the course of the OLE. Due to the potential of suppressing activation of both T and B cells over time, anti-CD40 therapies have long been considered a promising mechanism for control of MS. However, clinical development of first-generation drugs was abandoned because of an association with thromboembolism. 'Frexalimab has been engineered to avoid these events through a change in the Fc receptors with reduces downstream inflammatory events,' said Krieger. The long-term data support this premise. Over 2 years, there was one pulmonary embolism, but this exception was observed in a patient with a viral illness and a genetic predisposition for an inflammatory response, according to Krieger. When surveying other adverse events, 'nothing jumps out' in the OLE relative to the randomized phase. One potential exception is a rise in liver function tests observed in two (4%) patients on the 1200-mg dose. Only one of these patients discontinued therapy, and the levels returned to normal over time in both. The effects of the anti-CD40 mechanism on both the adaptive and innate immune systems suggest frexalimab might offer efficacy for both progressive and relapsing MS. In the ongoing phase 3 program, one of the trials (FREXALT) is enrolling patients with relapsing MS. The other (FREVIVA) is enrolling patients with progressive disease. Fulfilling its Promise Commenting on the results, Amit Bar-Or, MD, Chief of the Multiple Sclerosis Division, the Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, described frexalimab as 'a very interesting drug.' He agreed that the CD40 ligand is a promising target in MS but cautioned that these phase 2 data cannot answer the most interesting questions. This includes the more robust evidence of safety and efficacy from phase 3 trials, but it remains unclear whether the benefits extend beyond controlling relapsing disease. 'I think there is particular interest in whether it will also show extended benefit in progressive MS, and this will be a major focus of interest from the next set of studies,' Bar-Or said.
CBS News
an hour ago
- CBS News
Texas woman dies from brain-eating amoeba after using tap water for sinus rinse
How to stay safe from the brain-eating amoeba Parasite called Naegleria fowleri has been found in several states and is blamed for 3 deaths in the U.S. this year Parasite called Naegleria fowleri has been found in several states and is blamed for 3 deaths in the U.S. this year A Texas woman died from an infection caused by a brain-eating amoeba after using tap water in a nasal irrigation device, according to the Centers for Disease Control and Prevention. A case report from the agency said the woman died of primary amebic meningoencephalitis, or PAM, a rare but often fatal brain infection caused by the Naegleria fowleri organism. The previously healthy 71-year-old developed severe symptoms, including fever, headache and altered mental status, within four days after using the nasal irrigation device, the case report said. Despite medical treatment for a suspected PAM infection, eight days after the symptoms began, she developed seizures and died. The tap water she used for the sinus rinse came from an RV's water system at a campground in Texas, according to the case report. The CDC recommends the use of distilled, sterile or boiled and cooled tap water for nasal irrigation. PAM is also typically associated with recreational water activities, as the amoeba thrives in warm freshwater lakes, rivers and hot springs. Infections can occur if water containing the ameba goes up the nose and to the brain. To reduce your risk, the CDC suggests holding your nose or wearing a nose clip if you are jumping or diving into fresh water or keeping your head above water in hot springs. In rare cases, people have also become infected from pools and splash pads that did not have enough chlorine, the CDC says. You cannot, however, get a Naegleria fowleri infection from swallowing contaminated water or from someone else who is infected.
